Some experts express concern about ‘lack of transparency’ as agency removes warnings on three estrogen patches

Three more patches for treating menopause will no longer carry black-box warnings about cardiovascular disease, breast cancer and dementia, officials at the US Food and Drug Administration (FDA) said on Friday.

The FDA did not convene an advisory committee and offered few details on the scientific basis for the decision in the press briefing. The news follows the removal of black-box warnings from six menopause treatments in February, as patients across the US struggle with shortages of the patches.

In the late 2010s, a movement argued that no one body type is superior than another. Now in the GLP-1 age, people are still pursuing thinness - and just not talking about it

Vogue World Milano was held beneath the vaulted glass domes of Italy’s oldest shopping arcade, featuring Gigi Hadid in archival Valentino couture and robots dancing on the catwalk while Miuccia Prada scowled at them. A splashy event staged in the midst of a month of fashion shows in New York, London, Milan and Paris, in which 97.5% of models were a US size four or under, what ticked people off most was the presence of trillion-dollar pharma company Eli Lilly on the list of sponsors.

Eating disorder advocates spoke out against the association between an aspirational fashion show and the manufacturer of the weight-loss drugs Zepbound and Mounjaro.